Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the effect of BEPREVE compared to a REFRESH Tears Lubricant eye drop on the measurement of the wheal and flare from histamine skin prick testing. This is an open label, two-week, post-marketing study conducted on histamine responsive patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bepreve | Experimental | topical ocular treatment as indicated |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bepreve | Drug | Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| measurement of Wheal and Flare response from histamine skin-prick testing | 7 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bob Q Lanier, MD | North Texas Institute for Clinical Trials | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| North Texas Institute for Clinical Trials | Fort Worth | Texas | 76132 | United States |
Not provided
| ID | Term |
|---|---|
| D003233 | Conjunctivitis, Allergic |
| ID | Term |
|---|---|
| D003231 | Conjunctivitis |
| D003229 | Conjunctival Diseases |
| D005128 | Eye Diseases |
| D006969 | Hypersensitivity, Immediate |
Not provided
Not provided
| ID | Term |
|---|---|
| C511534 | bepotastine besilate |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Refresh Tears | Drug | Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment |
|
| D006967 |
| Hypersensitivity |
| D007154 | Immune System Diseases |